Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
$ERAS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US29479A1088
Website
Erasca Metrics
BasicAdvanced
$402M
-
-$0.59
1.13
-
Price and volume
Market cap
$402M
Beta
1.13
52-week high
$3.45
52-week low
$1.01
Average daily volume
1.5M
Financial strength
Current ratio
12.352
Quick ratio
12.056
Long term debt to equity
11.519
Total debt to equity
12.719
Profitability
EBITDA (TTM)
-145.537
Management effectiveness
Return on assets (TTM)
-22.16%
Return on equity (TTM)
-45.82%
Valuation
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-2.908
Free cash flow yield (TTM)
-34.39%
Free cash flow per share (TTM)
-48.84%
Growth
Earnings per share change (TTM)
-29.89%
3-year earnings per share growth (CAGR)
-27.63%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Bulls say / Bears say
Erasca secured approximately $184 million through an oversubscribed underwritten offering in May 2024, significantly bolstering its financial position to advance its oncology pipeline. (Erasca News Release)
Jefferies initiated coverage on Erasca with a 'Buy' rating and a $6.00 price target in November 2024, citing the potential of its RAS-targeted therapies and attractive valuation. (Investing.com)
BofA Securities upgraded Erasca's rating from 'Neutral' to 'Buy' in January 2025, reflecting increased confidence in the company's growth prospects. (Nasdaq)
JPMorgan Chase & Co. reduced its holdings in Erasca by 0.6% in the third quarter, indicating a slight decrease in institutional confidence. (ETF Daily News)
Janus Henderson Group PLC decreased its stake in Erasca by 49.7% during the third quarter, suggesting potential concerns about the company's performance. (ETF Daily News)
Despite recent capital raises, Erasca's stock price has remained relatively low, trading at $1.42 as of July 8, 2025, which may reflect ongoing market skepticism about its near-term profitability.
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Erasca News
AllArticlesVideos
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewsWire·1 month ago
Erasca Reports First Quarter 2025 Business Updates and Financial Results
GlobeNewsWire·2 months ago
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $402M as of July 08, 2025.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of July 08, 2025.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.